Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics

Journal of Neural Transmission, Supplement

Volumn , Issue 52, 1998, Pages 149-171

  Strolin Benedetti, M ^a   Tipton, K F ^b  

^a Zambon Group SpA   (Italy)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CYTOCHROME P450; DINUCLEOTIDE; FLAVINE ADENINE NUCLEOTIDE; POLYAMINE; SEMICARBAZIDE DERIVATIVE; XENOBIOTIC AGENT; CATECHOL METHYLTRANSFERASE; OXIDOREDUCTASE; POLYAMINE OXIDASE; TOXIN;

ARTICLE; CATALYSIS; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME METABOLISM; HUMAN; MENTAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; XENOBIOTIC METABOLISM; ANIMAL; BIOTRANSFORMATION; ENZYME SPECIFICITY; ENZYMOLOGY; METABOLISM; MICROSOME; REVIEW;

ANIMALS; BIOTRANSFORMATION; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES; MONOAMINE OXIDASE; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; SUBSTRATE SPECIFICITY; TOXINS, BIOLOGICAL; XENOBIOTICS;

EID: 0031627541     PISSN: 03036995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Beedham C (1985) Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 16: 119-156
2. Beresdorf AP, Macrae PV, Stopher DA (1988a) Metabolism of amlodipine in the rat and the dog: a species difference. Xenobiotica 18: 169-182
3. Beresdorf AP, McGibney D, Humphrey MJ, Macrae PV, Stopher DA (1988b) Metabolism and kinetics of amlodipine in man. Xenobiotica 18: 245-254
4. Bey P, Bolkenius FN, Seiler N, Casara P (1985) N-2,3-butadienyl-1,4-butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase. J Med Chem 28: 1-2
5. Bitonti AJ, Dumont JA, Bush TL, Stemerick DM, Edwards ML, McCann PP (1990) Bis(benzyl)polyamine analogs as novel substrates for polyamine oxidase. J Biol Chem 265: 382-388
6. Callingham BA, Holt A, Elliot J (1990) Some aspects of the pharmacology of semicarbazide-sensitive amine oxidases. J Neural Transm [Suppl] 32: 279-290
7. Cao Danh H, Strolin Benedetti M, Dostert P (1984) In: Tipton KF, Dostert P, Strolin Benedetti M (ed) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic Press, London, p 301
8. Cesura AM, Imhof R, Galva MD, Kettler R, Da Prada M (1988) Interactions of the novel inhibitors of MAO-B Ro 19-6327 and Ro 16-6491 with the active site of the enzyme. Pharmacol Res Commun 20 [Suppl IV]: 51-61
9. Clark AM, Baker JK, McChesney JD (1984) Excretion, distribution, and metabolism of primaquine in rats. J Pharm Sci 73: 502-506
10. Coomes MW, Prough RA (1983) The mitochondrial metabolism of 1,2-disubstituted hydrazines, procarbazine and 1,2-dimethylhydrazine. Drug Metab Dispos 11(6): 550-555
11. Della Corte L, Callingham BA (1977) The influence of age and adrenalectomy on rat heart monoamine oxidase. Biochem Pharmacol 26: 407-415
12. Dixon CM, Parkt GR, Parbit MH (1994) Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 42: 1253-1257
13. Dostert P, Strolin Benedetti M (1988) Les bases de la neurotoxicilé du MPTP. L'Encéphale 14: 399-412
14. Dostert P, Strolin Benedetti M, Tipton KF (1989) Interaction of monoamine oxidase with substrates and inhibitors. Med Res Rev 9: 45-89
15. Duine JA (1991) Quinoproteins: enzymes containing the quinonoid cofactor pyrroloquinoline quinone, topaquinone or tryptophan-tryptophan quinone. Eur J Biochem 200: 271-284
16. Edwards G, McGrath CS, Ward SA, Suparanond W, Pukrittayakamee S, Davis TME, White NJ (1993) Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br J Clin Pharmacol 35: 193-198
17. Fang J, Gorrod JW (1991) Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicol Lett 59: 117-123
18. Fang J, Rosen A, Gorrod JW (1993) Investigation of heterocyclic amines as potential substrates and inhibitors of monoamine oxidase. Pharm Sci Comm 4: 75-79
19. Ferkany JW, Andree TH, Clarke DE, Enna SJ (1981) Neurochemical effects of kojic amine, a gabamimetic, and its interaction with benzylamine oxidase. Neuropharmacology 20: 1177-1182
20. Fitton A, Benfield P (1990) Dopexamine hydrochloride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drugs 39(2): 308-330
21. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, Warner D, Zezulkova I, Cilento R (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379: 733-736
22. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS (1991) The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 31: 291-294
23. Freestone S, Li Kam Wa TC, Lee MR (1992) The effect of the monoamine oxidase-B inhibitor selegiline on the metabolism of y-L-glutamyl-L-dopa (gludopa) in man. Proceedings of the BPS, September 9-11, 1992, p 74
24. Garland WA, Miwa BJ, Dairman W, Kappell B, Chiueh MC, Divoll M, Greenblatt DJ (1983) Identification of 7-chloro-5-(2′-fluorophenyl)-2,3-dihydro-2-oxo-1H-1, 4-benzodiazepine-1-acetaldehyde, a new metabolite of flurazepam in man. Drug Metab Dispos 11: 70-72
25. Guengerich FP (1995) Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am J Clin Nutr 61 [Suppl]: 651S-658S
26. Halliwell B (1989) Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 126: 23-33
27. Holt A, Callingham BA (1994) The ex vivo effects of procarbazine and methylhydrazine on some rat amine oxidase activities. J Neural Transm 41: 439-443
28. Janssen de Varebeke P, Cavalier R, David-Remacle M, Youdim MBH (1988) Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B. J Neurochem 50: 1011-1016
29. Jeong TC, Yang KH, Holsapple MP (1994) Recovery of dimethylnitrosamine-induced immunosuppression by pargyline in the mixed cultures of murine hepatocytes and splenocytes. Life Sci 54(9): 605-613
30. Kenny P, Tipton KF, Strolin Benedetti M (1996) 6th Amine Rappaport Symposium and 7th International Amine Oxidase Workshop, Haifa, June 10-13, 1996. Book of Abstracts, p 40
31. Kinemuchi H, Fowler CJ, Tipton KF (1987) The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's disease. Neurochem Int 11: 359-373
32. Kopin IJ (1993) Monoamine oxidase (MAO): relationships to foods, poisons and medicines. Biogen Amines 9: 355-365
33. Lake BG, Phillips JC, Cottrell RC, Gangolli SD (1978) Biological oxidation of nitrogen. Elsevier/North Holland, New York, p 131
34. Lee PC, Werlin SL (1995) The induction of hepatic cytochrome P450 3A in rats: effects of age. P.S.E.B.M. 210: 134-139
35. Lewinsohn R (1984) Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues. Braz J Med Biol Res 17: 223-256
36. Liczano JM, Fernández de Arriba A, Lyles GA, Unzeta M (1994) Several aspects of the amine oxidation by semicarbazide-sensitive amine oxidase (SSAO) from bovine lung. J Neural Transm [Suppl] 41: 415-420
37. Lyles GA (1994) Properties of mammalian tissue-bound semicarbazide-sensitive amine oxidase: possible clues to its physiological function? J Neural Transm [Suppl] 41: 387-396
38. Lyles GA, Chalmers J (1992) The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem Pharmacol 43: 1409-1414
39. Lyles GA, Marshall CM, McDonald IA, Bey P, Palfreyman MG (1987) Inhibition of rat aorta semicarbazide-sensitive amine oxidase by 2-phenyl-3-haloallylamines and related compounds. Biochem Pharmacol 36: 2847-2853
40. Mageed AA, Williams D, Faray B, Messina C, Ragab AH (1993) The effect of prednisone therapy on platelet monoamine oxidase and plasma catecholamine levels in children with acute lymphocytic leukemia. Cancer Res Ther Control 3: 79-85
41. Maret G, Testa B, Jenner P, el Tayar N, Carrupt PA (1990) The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism. Drug Metab Rev 22: 291-332
42. Markey SP, Schmuff NR (1986) The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds. Med Res Rev 6: 389-429
43. McEwen CM, Harrison DC (1965) Abnormalities of serum monoamine oxidase in chronic congestive heart failure. J Lab Clin Med 65(4): 546-559
44. McEwen CM Jr, Castell DO (1967) Abnormalities of serum monoamine oxidase in chronic liver disease. J Lab Clin Med 70: 36-47
45. Mclntire WS (1992) Wither PQQ. Essays Biochem 27: 119-134
46. Mihaly GW, Ward SA, Edwards G, L'E Orme M, Breckenridge AM (1984) Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol 17: 441-446
47. Murata K, Noda K, Kohno K, Samejima M (1988) Bioavailability and pharmacokinetics of oral dopamine in dogs. J Pharm Sci 77(7): 565-568
48. Murphy PJ, Williams TL, Kau DLK (1976) Disposition of dobutamine in the dog. J Pharmacol Exp Ther 199(2): 423-431
49. Nelson TJ, Boor PJ (1982) Allylamine cardiotoxicity-IV metabolism to acrolein by cardiovascular tissues. Biochem Pharmacol 31: 509-514
50. Ni Y, Xu Y, Wang M (1992) In: Proceedings of the Fourth North American ISSX Meeting, Bal Harbour, FL, November 2-6, 1992, p 70
51. Nilsson SE, Tryding N, Tufvesson G (1968) Serum monoamine oxidase (MAO) in diabetes mellitus and some other internal diseases. Acta Med Scand 184: 105-108
52. Nishiyama S, Yoshikawa M, Yamaguchi I (1992) An orally effective peripheral dopamine prodrug: docarpamine (TA-870). Cardiovasc Drug Rev 10: 101-116
53. O'Brien EM, Tipton KF, Strolin Benedetti M, Bonsignori A, Marrari P, Dostert P (1991) Is the oxidation of milacemide by monoamine oxidase a major factor in its anti-convulsant actions? Biochem Pharmacol 41: 1731-1737
54. O'Brien EM, Dostert P, Pevarello P, Tipton KF (1994) Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase. Biochem Pharmacol 48: 905-914
55. O'Brien EM, Dostert P, Tipton KF (1995) Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B. Biochem Pharmacol 50: 317-324
56. Phillips JC, Bex C, Lake BG, Cottrell RC, Gangolli SD (1982) Inhibition of dimethylnitrosamine metabolism by some heterocyclic compounds and by substrates and inhibitors of monoamine oxidase in the rat. Cancer Res 42: 3761-3765
57. Precious E, Gunn CE, Lyles GA (1988) Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta. Biochem Pharmacol 37: 707-713
58. Roberts BJ, Shoaf SE, Jeong KS, Song BJ (1994) Induction of CYP2E1 in liver, kidney, brain and intestine during chronic ethanol administration and withdrawal: evidence that CYP2E1 possesses a rapid phase half-life of 6 hours or less. Biochem Biophys Res Commun 205: 1064-1071
59. 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12: 1977-1999
60. Saura J, Nadal E, van den Berg B, Vila' M, Richards JG, Bombi JA, Mahy N (1994) Localization of monoamine oxidases in human peripheral tissues. 6th Amine Oxidase Workshop and 5th Trace Amine Conference, Saskatoon, 31 July-3 August 1994. Book of Abstracts No A 03
61. Saura J, Richards JG, Mahy N (1994) Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol Aging 15: 399-408
62. Seaman CH, Palcic MM (1992) Stereochemical course of tyramine oxidation by semicarbazide-sensitive amine oxidase. Biochemistry 31: 6829-6841
63. Schwartz MA, Postma E (1970) Metabolism of flurazepam, a benzodiazepine, in man and dog. J Pharm Sci 59: 1800-1806
64. Seiler N (1987) In: McCann PP, Pegg AE, Sjoerdsma A (eds) Inhibition of polyamine metabolism. Academic Press, London, p 49
65. Seiler N, Bolkenius FN, Knodgen B, Mamont P (1980) Polyamine oxidase in rat tissues. Biochim Biophys Acta 615: 480-488
66. 14 in mice: effect of amine oxidase inhibitors on metabolism. Neuropharmacology 10: 547-556
67. Spencer C, Faulds D, Fitton A (1993) Ibopamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure. Drugs & Aging 3(6): 556-584
68. Steiner A, Walle UK, Walle T (1992) Induction of propranolol metabolism in the Hep G2 human hepatoma cell line. J Pharm Pharmacol 44: 611-614
69. Strolin Benedetti M, Dostert P (1992) Monoamine oxidase: from physiology and pathophysiology to the design and clinical application of reversible inhibitors. Drug Res 23: 65-125
70. Strolin Benedetti M, Dostert P (1994) Contribution of amine oxidases to the metabolism of xenobiotics. Drug Metab Rev 26: 507-535
71. Strolin Benedetti M, Rovei V, Thiola A, Donath A (1984) In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic Press, London, p 203
72. Strolin Benedetti M, Dostert P, Tipton KF (1988) Contributions of monoamine oxidase to the metabolism of xenobiotics. Progr Drug Metab 11: 149-174
73. Strolin Benedetti M, Allievi C, Cocchiara G, Pevarello P, Dostert P (1992) Involvement of FAD-dependent polyamine oxidase in the metabolism of milacemide in the rat. Xenobiotica 22(2): 191-197
74. Strolin Benedetti M, Marrari P, Colombo M, Castelli MG, Arand M, Oesch F, Dostert P (1994) The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. J Pharm Pharmacol 46: 814-819
75. Strolin Benedetti M, Sanson G, Bona L, Gallina M, Persiani S, Tipton KF (1996) 6th Amine Rappaport Symposium and 7th International Amine Oxidase Workshop, Haifa, June 10-13, 1996. Book of Abstracts, p 14
76. Subramanyam B, Rollema H, Woolf T, Castagnoli N Jr (1990) Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166: 238-244
77. Subramanyam B, Pond SM, Eyles DW, Whiteford HA, Fouda HG, Castagnoli N Jr (1991) Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem Biophys Res Commun 181: 573-578
78. Suzuki O, Matsumoto T, Katsumata Y (1984) Determination of polyamine oxidase activities in human tissues. Experientia 40: 838-839
79. Tateishi T, Fujimura A, Shiga T, Ohashi K, Ebihara A (1995) Influence of aging on the oxidative and conjugative metabolism of propranolol. Int J Clin Pharm Res XV(3): 95-101
80. Teramoto T, Takahashi N, Yamada F, Fukazawa I, Oguchi K, Yasuhara H (1987) Inhibitory effects of antiarrhythmic drugs on rat heart and liver monoamine oxidase. Asia Pac J Pharmacol 2: 275-279
81. Tetrud JW, Langston JW (1989) MPTP-induced parkinsonism as a model for Parkinson's disease. Acta Neurol Scand [Suppl] 126: 35-40
82. Thomas PE, Bandiera S, Maines SL, Ryan DE, Levin W (1987) Regulation of cytochrome P-450j, a high-affinity N-nitrosodimethylamine demethylase, in rat hepatic microsomes. Biochemistry 26: 2280-2289
83. Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61: 1191-1206
84. Worth DP, Harvey JN, Brown J, Lee MR (1985) y-L-Glutamyl-L-dopa is a dopamine prodrug, relatively specific for the kidney in normal subjects. Clin Sci 69: 207-214
85. Yoshikawa M, Endo H, Komatsu K, Fujihara M, Takaiti O, Kagoshima T, Umehara M, Ishikawa H (1990) Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis (ethoxycarbonyl) dopamine (TA-870) in humans. Drug Metab Dispos 18(2): 212-217
86. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T (1995) Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 39: 421-431
87. Yu PH, Davis BA (1991a) 2-propyl-1-aminopentane, its deamination by monoamine oxidase and semicarbazide-sensitive amine oxidase, conversion to valproic acid and behavioral effects. Neuropharmacology 30: 507-515
88. Yu PH, Davis BA (1991b) Simultaneous delivery of valproic acid and glycine to the brain. Deamination of 2-propylpentylglycinamide by monoamine oxidase B. Mol Chem Neuropathol 15: 37-49
89. Yu PH, Tipton KF (1989) Deuterium isotope effect of phenelzine on the inhibition of rat liver mitochondrial monoamine oxidase activity. Biochem Pharmacol 38(23): 4245-4251
90. Ziegler DM (1988) Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metab Rev 19: 1-32